Explore the history that shaped Resolian and get a sneak peek into our future plans with our new video series. 

In the series of nine videos our CEO, Patrick Bennett explains the journey behind our recent rebranding and future plans in an insightful interview with Chris O'Connor from Life Science Marketing Radio.

Chapter 1 - "We Are Resolian"

Discover the journey behind our recent rebranding directly from our CEO, Patrick Bennett, in an insightful interview with Chris O'Connor from Life Science Marketing Radio.

Get ready for an exclusive look into the heart of Resolian, as we share our resolution to be one of the best laboratories globally committed to our purpose and mission in serving customers and our scientific staff.

🎬 Watch the video here: 

Chapter 2 - "One Global Organization"

Our journey into becoming a unified global entity in just 15 months has set the stage for unparalleled flexibility and efficiency. The decision to consolidate under one name allows the organization to function seamlessly as a single entity, providing clients with the flexibility to manage clinical trials across the strategically located laboratories in the US, Europe, China, and Australia.

🎬 Watch the video below.

Chapter 3 - "Empowering Global Collaboration"

The acquisition of China-based Denali Medpharma in November 2023 marks a significant leap forward in our global capabilities, particularly benefiting clients navigating the complexities of the Chinese market.

With a team of high-quality scientists, the lab brings valuable expertise, bridging the gap for companies unfamiliar with the intricacies of operations in China. Our unique advantage lies in seamless method transfers between Western pharma clients and the China lab.

🎬 Watch the video here to find out more about what the new lab in China means for our clients.

Read more about the Resolian acquisition of Denali Medpharma here: 

Chapter 4 - "Australia Lab - Accelerating Success"

The Australia lab emerges as a game-changer for clients seeking accelerated timelines and financial advantages in early-phase clinical studies. The regulatory landscape in Australia facilitates faster initiation of first-in-human studies compared to the US and Europe, supported by a network of robust clinical facilities.

Beyond speed, there is also a financial benefit to conducting trials in Australia.

Companies can claim 43.5% R&D cash refund with the Australian Government clinical trial rebate program, delivering a dual advantage in both efficiency and finance.

🎬 Watch the video here to find out more about Resolian’s Australian lab.

Chapter 5 - "Logistics Mastery for Seamless Global Operations"

Handling samples across borders involves intricate considerations, from stability to hazards. Resolian's expertise shines in navigating these complexities, particularly evident in China where HGRAC regulations pose challenges to the movement of human-based samples.

🎬 Watch the video here to find out more about Resolian’s logistics capabilities.

Chapter 6 - "Tailored Solutions for Sponsors"

Sponsors often manage a portfolio of vendors. Most want to have some larger full-service companies in their portfolio of bioanalytical vendors. Depending on the project, those full-service vendors aren’t always the right fit. Most of them are not global. A sponsor might take advantage of one component of their service but are not necessarily what you need for this specific project.

There is always a need for laboratories like Resolian that are focused on bioanalysis.

🎬 Watch the video here to find out more about Resolian’s responsiveness and flexibility.

Chapter 7 - "Diverse Analytical Prowess Unveiled"

Unlocking the depths of Resolian's analytical capabilities reveals a remarkable breadth across various specialties. While many labs excel in specific areas, each of Resolian's entities stands out for its comprehensive strength. With extensive experience ranging from immunoassay to LCMS, including small molecules, large molecules, biologics, and oligonucleotides, Resolian covers a spectrum of analytical domains.

🎬 Watch the video here to find out more about the diverse analytical skills at Resolian.

Chapter 8 - "Balancing Unity and Uniqueness"

Four bioanalytical labs, four continents.

Navigating the question of maintaining consistency, Resolian unveils a dual approach to harmonize operations seamlessly. While integration is implemented for non-scientific functions, ensuring universal policies with local modifications, the scientific operations follow a unique path of harmonization.

🎬 Watch the video here to find out more about our goal to create a familiar environment for legacy customers, facilitating flexibility between geographies.

Chapter 9 - "Unveiling the Heartbeat - Bringing Benefits to Patients!”

In this final instalment, we explore Resolian's impact on patients' experiences in clinical trials. Unlike central labs or clinical diagnostics, bioanalysis often involves unique methods, limiting optimal locations for sample analysis.

Resolian's global network, with laboratories in multiple geographies, provides our pharma clients the leverage to strategically choose where they run analyses in alignment with their clinical trials. This not only expands the options for clients but, more importantly, broadens the reach of clinical trials, benefiting a larger population of patients around the globe.

Our advanced scientific infrastructure and world-class experts attract trials from across the globe and meet their needs with the highest standards and efficient regulatory requirements.

Explore the extensive benefits of Australia’s clinical research ecosystem below.

1. GLOBALLY ACCEPTED DATA
   Alliance Pharma has a world-class reputation for quality data, following the highest level of GCP and ICH standards. Data from clinical trials conducted in Australia is widely accepted by all regulatory authorities including FDA and EMA.
   
   
2. EXTEND YOUR BUDGET BY 43.5%
    includes bioanalytics services
    almost halve your clinical trial costs
   
   You can claim R&D cash refund with the Australian Government clinical trial rebate program. As an example, if you spend $200k on eligible R&D, you can receive $87k (43.5%) back from the Australian Tax Office (ATO). This effectively means you could turn $1million dollars into $1.7 million dollars of research spend in just three years.
   
   
3. RAPID START-UP & APPROVAL
    The Australian Regulatory Framework is the fastest in the world for undertaking early phase clinical research trials
    Trials can start in 4-8 weeks compared to 10 months in the US.
    No IND required for clinical trials. Save up to a year in regulatory timelines and considerable costs.
   
   
4. INDUSTRY-LEADING TECHNOLOGY
   Clinical trials are resource-intensive processes requiring the availability of state-of-the-art equipment and facilities for testing and analysis. We have invested heavily in the industry-leading technology platforms to support speed, communications, and regulatory compliance.
   
   
5. GLOBAL CAPABILITIES
   Local relationships, global execution As a global contract research organization – with sites in USA and UK – we can provide internal assay transfer and validation protocols among our global sites.
   
   Harmonized SOPs, policies, and IT systems to facilitate transfer of methods, data, and information enable you to reduce time, risk, and cost.
   
   
6. SEASONAL DIFFERENCES
   Seasonal differences to Europe and US, and time differences (our Australia lab works while you sleep)Seasonal differences between Australia and Europe or the US allow for yearlong participant recruitment for trials involving seasonal illnesses such as flu or allergies and allows researchers to cover seasonal variations in patient recruitment.
   
   
7. HEALTHCARE ENVIRONMENT
   Australian clinical practices and some aspects of its health care system are similar to the United States, United Kingdom and most of Europe.
   
   
8. DIVERSE PARTICIPANT RECRUITMENT
   The willingness of potential participants and their knowledge of clinical trials is another attractive option for sponsors to conduct trials in Australia.
   
   A mixed population of Caucasians and Asian adds diversity to the participant pool and enables ethnicity differences in treatment response to be studied.
   
   

Need Support to Conduct Clinical Trials in Australia?  Contact Alliance!

As a CRO, meeting client expectations can be an ongoing challenge. What can organisations do to make sure their research is as effective and efficient as possible?

In the Autumn 2022 issue of European Pharmaceutical Contractor magazine, the leadership team from Alliance Pharma reviews what CRO organisations can do to make sure their research is as effective and efficient as possible while meeting the ongoing challenge of their customer's expectations.

Patrick Bennett, Jean Pierre Boutrand, and Vito Saccente at Alliance Pharma

Serving clients is the core of a contract research organisation’s (CRO) business. The more comprehensive a CRO’s service offerings, the more likely it is to attract and retain clients. Recent events – like the COVID-19 pandemic – have set in motion industry shifts. Such shifts demand CROs adapt so that they can continue meeting their clients’ evolving needs . . .

READ MORE

Alliance Pharma is dedicated to bringing comprehensive solutions to our collaborative partnerships.  We understand the importance of efficiency and our team of scientists strive to provide the highest analytical services for your project. 

Our recent purchase of multiple Agilent 6545XT AdvanceBio QTOFs – which is specifically designed with biopharmaceutical characterization in mind - provides high resolution and sensitivity for qualitative and quantitative analyses of biomolecules ranging from peptides to intact monoclonal antibodies. The iterative peptide mapping workflow allows us to dig deep into samples with a wide range of analyte concentrations (i.e. host cell proteins and sequence variants). The Agilent 6545XT AdvanceBio QTOF maximizes our uptime by performing thousands of protein injections without degradation of performance with mass accuracies within 10 ppm for glycosylated intact proteins. 

At Alliance Pharma we believe keeping up with the latest technology helps us to provide the best services for our clients.  The 1290 Infinity II LC system when coupled with the 6545XT, represents the next generation LC for ultrahigh-performance liquid chromatography with superior reliability, offering efficient and reproducible separations of biomolecules for detection by MS or integrated UV and FLD modules. 

By using instruments that complement our scientist’s knowledge and experience we meet analytical objectives, increase productivity, and are cost-effective.  Contact us to see how our recent instrument purchase will help keep your project on track.  Call or email Ryan at 919-801-3146 or  rklein@alliancepharmaco.com for more information.

Alliance Pharma has hired Dr. Ryan Klein as Director of Business Development. Dr. Klein has more than 20 years of experience in the pharmaceutical industry developing both oral and topical dosage forms for a range of indications. Dr. Klein began his career at GlaxoSmithKline, where he was an integral component of their drug discovery organization providing drug metabolism and pharmacokinetic expertise to project teams. He was instrumental in the development and implementation of a number of in vitro and in situ ADME models to assess drug absorption, metabolism, and disposition.

After leaving GSK, Dr. Klein joined Tergus Pharma, a CRO providing topical R&D services to the pharmaceutical industry. At Tergus, Ryan filled various roles including leadership positions as the Head of Research & Development and Head of In Vitro Sciences, as the company grew from five employees to approximately seventy five over a seven year period.

Dr. Klein’s areas of expertise include drug permeability, absorption and metabolism in the gastrointestinal tract, liver and skin, intestinal drug transporters, and the anatomy, physiology, and pharmacology of the skin and GI tract. He also has a strong analytical background with extensive experience developing and validating in vitro release testing methods for semi-solid dosage forms, as well as developing and validating HPLC assay and impurities methods.

Leveraging Dr. Klein’s experience on the client side allows Alliance Pharma to collaborate on a higher level with Sponsors, using his in-depth knowledge and vast experience to align the best team of scientists to support each project.

Ryan earned his bachelor’s degree in Chemistry from Wake Forest University in Winston-Salem, North Carolina, and earned his doctoral degree in Pharmaceutical Sciences from the School of Pharmacy at the University of North Carolina at Chapel Hill. Ryan has authored & co-authored numerous scientific publications and patents, and serves as a member of several pharmaceutical research focus and discussion groups.

To read more or to connect with Ryan, view his LinkedIn profile https://www.linkedin.com/in/ryanrklein/

Colin Barry, Ph.D. & Scott Ugrin, Ph.D.

Alliance Pharma’s bioanalytical team provides comprehensive services for both small and large molecules using a variety of platforms from mass spectrometry to ligand binding assays using an assortment of specialized instrumentation. Our analytical laboratories boast thirteen LC-MS/MS systems from three different manufacturers and include various platforms. Nine systems from AB Sciex are each coupled to Shimadzu UHPLC systems, including two API4000 QTRAP systems, two API4000 triple quad systems, three 5500 triple quad systems, and two 6500 triple quad systems. Each system is designed for high sensitivity quantitative analysis of small molecules generated from either in vitro or in vivo studies and in various matrices.

Alliance Pharma’s small molecule mass-spec based bioanalytical team specializes in:

• Development, optimization, and transfer of bioanalytical assays
• Method Validation
• Sample analysis to support clinical (GLP) and non-clinical studies
• Plasma, serum, whole blood, and all tissue types
• Biomarker assay development, validation and sample analysis
• High throughput screening from in vitro ADME assays
• Metabolite identification

The newest additions to the bioanalytical lab include two Agilent 6545 XT Q-ToF high resolution mass spectrometers coupled to Agilent 1290 Infinity II UHPLC systems with PDA and FL detectors. These new systems add additional capacity to our existing high-resolution accurate-mass (HRAM) systems: 1) a Dionex RSLCnano, 2-D nano/micro/cap UHPLC system coupled to a Q Exactive Plus, and 2) an Orbitrap XL from Thermo Scientific. The newest HRAM systems are ideally suited for analysis of proteins and peptides and will allow generation of highly detailed information for intact proteins and antibodies, confirmation of sequence at the peptide level, and sophisticated analysis of both simple and comprehensive post-translational modifications.

The combination of mass accuracy (> 1 ppm) and high resolution (up to 280,000 at m/z 200) allow for increased specificity and sensitivity in extremely complex matrices. The additional capabilities position Alliance Pharma to continue to expand our large molecule qualitative and quantitative analysis capabilities.